Septerna, Inc. Common Stock (SEPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SEPN trades at $28.01 with a market cap of $1.19B and a P/E ratio of -33.78. SEPN moved +5.70% today. Year to date, SEPN is +4.55%; over the trailing twelve months it is +197.35%. Its 52-week range spans $4.17 to $32.63. Analyst consensus is strong buy with an average price target of $42.25. Rallies surfaces SEPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Septerna posts $522M cash, Q1 revenue $26.5M; advances SEP-631, launches SEP-479 trial: Septerna reported $522.1 million in cash and equivalents as of March 31, 2026, securing runway into 2029 and posted Q1 revenue of $26.5 million from its Novo Nordisk collaboration. The clinical-stage biotech advanced SEP-631 with positive Phase 1 data and initiated a Phase 1 trial of SEP-479 in hypoparathyroidism.
| Metric | Value |
|---|---|
| Price | $28.01 |
| Market Cap | $1.19B |
| P/E Ratio | -33.78 |
| EPS | $-0.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.63 |
| 52-Week Low | $4.17 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $72.25M |
| Net Income | $-36.04M |
| Gross Margin | 0.00% |
6 analysts cover SEPN: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.25.